16 The Korean Journal of Internal Medicine Vol. 26, No. 1, March 2011 REFERENCES 1. Barnes PJ. The cytokine network in asthma and chronic obstruc- tive pulmonary disease. J Clin Invest 2008;118:3546-3556. 2. Wills-Karp M, Finkelman FD. Untangling the complex web of IL- 4- and IL-13-mediated signaling pathways. Sci Signal 2008;1:pe55. 3. Smith WL, Meade EA, DeWitt DL. Pharmacology of prostaglandin endoperoxide synthase isozymes-1 and -2. Ann N Y Acad Sci 1994;714:136-142. 4. Fujitani Y, Kanaoka Y, Aritake K, Uodome N, Okazaki-Hatake K, Urade Y. Pronounced eosinophilic lung inflammation and Th2 cytokine release in human lipocalin-type prostaglandin D syn- thase transgenic mice. J Immunol 2002;168:443-449. 5. Mandal AK, Zhang Z, Ray R, et al. Uteroglobin represses allergen- induced inflammatory response by blocking PGD2 receptor- mediated functions. J Exp Med 2004;199:1317-1330. 6. Honda K, Arima M, Cheng G, et al. Prostaglandin D2 reinforces Th2 type inflammatory responses of airways to low-dose antigen through bronchial expression of macrophage-derived chemokine. J Exp Med 2003;198:533-543. 7. Urade Y, Ujihara M, Horiguchi Y, Ikai K, Hayaishi O. The major source of endogenous prostaglandin D2 production is likely anti- gen-presenting cells. Localization of glutathione-requiring prostaglandin D synthetase in histiocytes, dendritic, and Kupffer cells in various rat tissues. J Immunol 1989;143:2982-2989. 8. Tanaka K, Ogawa K, Sugamura K, Nakamura M, Takano S, Nagata K. Cutting edge: differential production of prostaglandin D2 by human helper T cell subsets. J Immunol 2000;164:2277- 2280. 9. Murray JJ, Tonnel AB, Brash AR, et al. Release of prostaglandin D2 into human airways during acute antigen challenge. N Engl J Med 1986;315:800-804. 10. Naclerio RM, Meier HL, Kagey-Sobotka A, et al. Mediator release after nasal airway challenge with allergen. Am Rev Respir Dis 1983;128:597-602. 11. Charlesworth EN, Kagey-Sobotka A, Schleimer RP, Norman PS, Lichtenstein LM. Prednisone inhibits the appearance of inflam- matory mediators and the influx of eosinophils and basophils associated with the cutaneous late-phase response to allergen. J Immunol 1991;146:671-676. 12. Benyon RC, Robinson C, Church MK. Differential release of hista- mine and eicosanoids from human skin mast cells activated by IgE-dependent and non-immunological stimuli. Br J Pharmacol 1989;97:898-904. 13. Schulman ES, Newball HH, Demers LM, Fitzpatrick FA, Adkinson NF Jr. Anaphylactic release of thromboxane A2, prostaglandin D2, and prostacyclin from human lung parenchy- ma. Am Rev Respir Dis 1981;124:402-406. 14. Hirata M, Kakizuka A, Aizawa M, Ushikubi F, Narumiya S. Molecular characterization of a mouse prostaglandin D receptor and functional expression of the cloned gene. Proc Natl Acad Sci U S A 1994;91:11192-11196. 15. Boie Y, Sawyer N, Slipetz DM, Metters KM, Abramovitz M. Molecular cloning and characterization of the human prostanoid DP receptor. J Biol Chem 1995;270:18910-18916. 16. Hirai H, Tanaka K, Yoshie O, et al. Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J Exp Med 2001;193:255-261. 17. Sawyer N, Cauchon E, Chateauneuf A, et al. Molecular pharma- cology of the human prostaglandin D2 receptor, CRTH2. Br J Pharmacol 2002;137:1163-1172. 18. Giles H, Leff P, Bolofo ML, Kelly MG, Robertson AD. The classifi- cation of prostaglandin DP-receptors in platelets and vasculature using BW A868C, a novel, selective and potent competitive antagonist. Br J Pharmacol 1989;96:291-300. 19. Whittle BJ, Hamid S, Lidbury P, Rosam AC. Specificity between the anti-aggregatory actions of prostacyclin, prostaglandin E1 and D2 on platelets. Adv Exp Med Biol 1985;192:109-125. 20. Tilley SL, Coffman TM, Koller BH. Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. J Clin Invest 2001;108:15-23. 21. Gervais FG, Cruz RP, Chateauneuf A, et al. Selective modulation of chemokinesis, degranulation, and apoptosis in eosinophils through the PGD2 receptors CRTH2 and DP. J Allergy Clin Immunol 2001;108:982-988. 22. Monneret G, Gravel S, Diamond M, Rokach J, Powell WS. Prostaglandin D2 is a potent chemoattractant for human eosinophils that acts via a novel DP receptor. Blood 2001;98:1942- 1948. 23. Angeli V, Staumont D, Charbonnier AS, et al. Activation of the D prostanoid receptor 1 regulates immune and skin allergic responses. J Immunol 2004;172:3822-3829. 24. Yoshimura-Uchiyama C, Iikura M, Yamaguchi M, et al. Differential modulation of human basophil functions through prostaglandin D2 receptors DP and chemoattractant receptor- homologous molecule expressed on Th2 cells/DP2. Clin Exp Allergy 2004;34:1283-1290. 25. Hammad H, de Heer HJ, Soullie T, Hoogsteden HC, Trottein F, Lambrecht BN. Prostaglandin D2 inhibits airway dendritic cell migration and function in steady state conditions by selective activation of the D prostanoid receptor 1. J Immunol 2003;171:3936- 3940. 26. Faveeuw C, Gosset P, Bureau F, et al. Prostaglandin D2 inhibits the production of interleukin-12 in murine dendritic cells through multiple signaling pathways. Eur J Immunol 2003;33:889-898.